Our Discovery Platform Mines Microbial Genomes to Deliver Novel Bioactive Molecules for Broad Therapeutic Impact.
Genevive’s science harnesses the profound influence the microbiota has on human health and disease. Through advanced data science, differential analysis, and machine learning, our discovery platform systematically mines microbial genomes to uncover novel compounds associated with and capable of modulating key host pathways—including immune regulation, tissue repair, metabolic function, and neurological health. By pairing microbiome differences with host gene expression datasets and applying rational-designed selection criteria, we identify bioactive molecules that have potential therapeutic benefit. These compounds are advance through phenotypic and functional screening to characterize targets and pathways, mechanisms of action, and in vivo potency—generating a robust, disease-agnostic pipeline of innovative therapeutic programs across multiple areas.
Genevive’s discovery platform is a disease agnostic approach to identify novel peptides and metabolites from the microbial world.
